Us Bancorp De Decreased By $771,764 Its F5 Networks (FFIV) Stake; Biohaven Pharmaceutical Holding Company LTD. Commo (BHVN) Sellers Decreased By 0.28% Their Shorts

September 14, 2018 - By Estela Ashley

F5 Networks, Inc. (NASDAQ:FFIV) Logo

Biohaven Pharmaceutical Holding Company LTD. Commo (NYSE:BHVN) had a decrease of 0.28% in short interest. BHVN’s SI was 2.76 million shares in September as released by FINRA. Its down 0.28% from 2.76 million shares previously. With 233,100 avg volume, 12 days are for Biohaven Pharmaceutical Holding Company LTD. Commo (NYSE:BHVN)’s short sellers to cover BHVN’s short positions. The SI to Biohaven Pharmaceutical Holding Company LTD. Commo’s float is 10.52%. The stock decreased 0.23% or $0.085 during the last trading session, reaching $37.285. About 22,830 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has risen 1.45% since September 14, 2017 and is uptrending. It has underperformed by 14.17% the S&P500. Some Historical BHVN News: 19/04/2018 – Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles; 06/03/2018 Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis┬« ODT In The Acute Treatment Of Migraine; 30/04/2018 – Biohaven Pharmaceutical Holding Closes Above 200-D-MA; 15/05/2018 – Biohaven Pharma 1Q Loss $85.5M; 26/03/2018 – BIOHAVEN RIMEGEPANT MET CO-PRIMARY ENDPOINT IN PHASE 3 TRIALS; 03/04/2018 – Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer; 06/03/2018 – Biohaven Enrolls First Patient in Phase 3 Clinical Trial to Evaluate Rimegepant Zydis ODT in the Acute Treatment of Migraine; 26/03/2018 – BIOHAVEN PHARMACEUTICAL SAYS IN TERMS OF COMPARISON OF RIMEGEPANT WITH ALLERGAN’S UBROGEPANT, THE SAFETY PROFILE THUS FAR FAVOURS RIMEGEPANT – CONF CALL; 19/04/2018 – Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon Enterprise, Tutor Pe; 09/05/2018 – Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS┬« Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)

Us Bancorp De decreased F5 Networks Inc (FFIV) stake by 23.84% reported in 2018Q2 SEC filing. Us Bancorp De sold 4,487 shares as F5 Networks Inc (FFIV)’s stock rose 6.01%. The Us Bancorp De holds 14,338 shares with $2.47M value, down from 18,825 last quarter. F5 Networks Inc now has $11.73 billion valuation. The stock increased 0.30% or $0.57 during the last trading session, reaching $192.84. About 54,031 shares traded. F5 Networks, Inc. (NASDAQ:FFIV) has risen 62.09% since September 14, 2017 and is uptrending. It has outperformed by 46.47% the S&P500. Some Historical FFIV News: 25/04/2018 – F5 Networks Sees 3Q EPS $1.79-EPS $1.82; 25/04/2018 – F5 Announces New Application Services Offering for Multi-Cloud Environments; 25/04/2018 – F5 Networks 2Q Adj EPS $2.31; 21/05/2018 – F5’S FRANCIS J. PELZER FORMERLY COO OF SAP CLOUD BUSINESS GROUP; 21/04/2018 – DJ F5 Networks Inc, Inst Holders, 1Q 2018 (FFIV); 25/04/2018 – F5 Networks: Pelzer to Succeed Andrew Reinland on May 21; 21/05/2018 – F5 Appoints Francis J. Pelzer As Chief Financial Officer; 25/04/2018 – F5 Networks 2Q Rev $533.3M; 25/04/2018 – F5 Networks 2Q Net $109.6M; 25/04/2018 – F5 NETWORKS NAMES FRANK PELZER EVP, CFO EFFECTIVE MAY 21

Another recent and important F5 Networks, Inc. (NASDAQ:FFIV) news was published by which published an article titled: “F5 to Present at Citi’s 2018 Global Technology Conference” on September 05, 2018.

Us Bancorp De increased Raytheon Company (NYSE:RTN) stake by 7,115 shares to 416,425 valued at $80.44 million in 2018Q2. It also upped Costco Whsl Corp (NASDAQ:COST) stake by 2,604 shares and now owns 532,696 shares. Vanguard Global Ex U S Real Et (VNQI) was raised too.

Among 11 analysts covering F5 Networks (NASDAQ:FFIV), 6 have Buy rating, 2 Sell and 3 Hold. Therefore 55% are positive. F5 Networks had 15 analyst reports since April 13, 2018 according to SRatingsIntel. The rating was initiated by J.P. Morgan on Thursday, May 3 with “Buy”. The company was maintained on Thursday, April 26 by Barclays Capital. The rating was upgraded by William Blair to “Buy” on Friday, April 13. The stock has “Hold” rating by Standpoint Research on Monday, June 18. The firm has “Buy” rating by BMO Capital Markets given on Thursday, May 31. Credit Suisse maintained F5 Networks, Inc. (NASDAQ:FFIV) rating on Wednesday, September 5. Credit Suisse has “Outperform” rating and $216 target. Bank of America maintained the shares of FFIV in report on Monday, June 11 with “Buy” rating. The firm has “Underweight” rating given on Thursday, July 19 by Morgan Stanley. The company was maintained on Sunday, May 20 by BMO Capital Markets. The stock of F5 Networks, Inc. (NASDAQ:FFIV) has “Buy” rating given on Wednesday, April 25 by BMO Capital Markets.

Investors sentiment increased to 1.01 in 2018 Q2. Its up 0.04, from 0.97 in 2018Q1. It improved, as 36 investors sold FFIV shares while 169 reduced holdings. 68 funds opened positions while 140 raised stakes. 58.10 million shares or 4.73% more from 55.47 million shares in 2018Q1 were reported. Swiss State Bank owns 312,364 shares. State Of Tennessee Treasury Department owns 0.15% invested in F5 Networks, Inc. (NASDAQ:FFIV) for 177,271 shares. Jpmorgan Chase & Co reported 446,634 shares stake. Pggm Invests holds 0.25% of its portfolio in F5 Networks, Inc. (NASDAQ:FFIV) for 260,401 shares. Covington Management holds 192 shares. Stone Ridge Asset Mngmt Ltd Liability accumulated 9,955 shares. Ascend Cap Limited Co reported 0.66% in F5 Networks, Inc. (NASDAQ:FFIV). Great Lakes Advsr Ltd Limited Liability Company stated it has 4,011 shares or 0.02% of all its holdings. Nine Masts Capital Limited holds 0% or 18 shares. Todd Asset Mngmt Limited Liability Company reported 333,468 shares. Hanson Mcclain reported 15 shares. First Republic Invest Management Inc owns 2,327 shares for 0% of their portfolio. Robeco Institutional Asset Bv owns 268,181 shares. Lenox Wealth Management holds 0.01% in F5 Networks, Inc. (NASDAQ:FFIV) or 104 shares. Employees Retirement System Of Texas has invested 0.02% of its portfolio in F5 Networks, Inc. (NASDAQ:FFIV).

Analysts await F5 Networks, Inc. (NASDAQ:FFIV) to report earnings on October, 24. They expect $2.12 EPS, up 7.07% or $0.14 from last year’s $1.98 per share. FFIV’s profit will be $128.93 million for 22.74 P/E if the $2.12 EPS becomes a reality. After $2.02 actual EPS reported by F5 Networks, Inc. for the previous quarter, Wall Street now forecasts 4.95% EPS growth.

Since May 1, 2018, it had 0 buys, and 14 insider sales for $16.26 million activity. Chadwick Jonathan also sold $433,427 worth of F5 Networks, Inc. (NASDAQ:FFIV) shares. 2,738 shares were sold by Rogers Scot Frazier, worth $446,238 on Tuesday, May 1. On Monday, June 11 the insider Locoh-Donou Francois sold $1.18 million. The insider Dreyer Michael L sold $1.04 million. Reinland Andrew sold $3.24M worth of stock. Shares for $4.33 million were sold by MCADAM JOHN. $1.15M worth of F5 Networks, Inc. (NASDAQ:FFIV) was sold by DiLullo John D on Thursday, May 3.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $1.50 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

More news for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) were recently published by:, which released: “Biohaven (BHVN) Reports FDA Submission of IND for BHV-3500 to Evaluate Safety and Tolerability” on September 12, 2018.‘s article titled: “Biohaven licenses MPO inhibitor from AstraZeneca for the treatment of MSA” and published on September 05, 2018 is yet another important article.

F5 Networks, Inc. (NASDAQ:FFIV) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts